Einzeltreffer — DigiBib

Background: Interferon-inducible protein-10 (IP-10) and monokine induced by interferon-gamma (MIG) are chemokines recognized as inflammatory biomarkers during HIV-1 infection. We assessed their early and long-term dynamics after initiation of antiretroviral treatment (ART).

Methods: Persons with HIV-1 (PWH) aged>18 years starting their first ART in 2015-2021 in a prospective cohort (n=73) were included. IP-10 and MIG plasma levels were quantified using a multiplexed bead-based assay.

Results: IP-10 and MIG plasma levels showed a significant and consistent reduction following ART (80% integrase inhibitor [INSTI]-based) initiation, starting at day 20 and maintained throughout the study period (48 months), paralleling the HIV-1 RNA decay and CD4+ count recovery (p<0·001). At baseline, PWH≥ 50 years, CDC stage C and CD4+ count<350cells/mm 3 had higher levels of IP-10 (p=0·022, p=0·001 and p=0·002, respectively) and MIG (p<0·001, p=0·024 and p=0·069, respectively). All of them matched their counterparts several months following ART initiation. MIG levels showed a greater decrease at day 10 in those treated with INSTI (p=0·038). Low-level HIV-1 viremia did not impact MIG or IP-10 levels.

Conclusion: Plasma IP-10 and MIG showed an early significant decline following ART initiation, with greater early declines in MIG levels in INSTI-based regimens. These findings suggest a strong impact of HIV-1 viremia on IP-10 and MIG levels.

Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

(Copyright © 2023 Álvarez, Gutiérrez-Valencia, Mariño, Saborido-Alconchel, Calderón-Cruz, Pérez-González, Alonso-Domínguez, Martínez-Barros, Gallego-Rodríguez, Moreno, Aldamiz, Montero-Alonso, Bernal, Galera, Llibre and Poveda.)

Titel:	IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors.
Autor/in / Beteiligte Person:	Álvarez, H ; Gutiérrez-Valencia, A ; Mariño, A ; Saborido-Alconchel, A ; Calderón-Cruz, B ; Pérez-González, A ; Alonso-Domínguez, J ; Martínez-Barros, I ; Gallego-Rodríguez, M ; Moreno, S ; Aldamiz, T ; Montero-Alonso, M ; Bernal, E ; Galera, C ; Llibre, JM ; Poveda, E
Link:	Full Text Finder (Volltext)
Zeitschrift:	Frontiers in immunology, Jg. 14 (2023-10-18), S. 1257725
Veröffentlichung:	[Lausanne : Frontiers Research Foundation], 2023
Medientyp:	academicJournal
ISSN:	1664-3224 (electronic)
DOI:	10.3389/fimmu.2023.1257725
Schlagwort:	Humans Interferon-gamma pharmacology Chemokine CXCL10 Prospective Studies Viremia HIV Integrase Inhibitors pharmacology HIV Integrase Inhibitors therapeutic use HIV-1
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Front Immunol] 2023 Oct 18; Vol. 14, pp. 1257725. <i>Date of Electronic Publication: </i>2023 Oct 18 (<i>Print Publication: </i>2023). MeSH Terms: HIV Integrase Inhibitors* / pharmacology ; HIV Integrase Inhibitors* / therapeutic use ; HIV-1* ; Humans ; Interferon-gamma / pharmacology ; Chemokine CXCL10 ; Prospective Studies ; Viremia References: Curr Opin HIV AIDS. 2014 Jan;9(1):72-9. (PMID: 24247669) ; J Infect Dis. 2016 Oct 1;214 Suppl 2:S44-50. (PMID: 27625430) ; AIDS Res Ther. 2020 Oct 14;17(1):61. (PMID: 33054784) ; J Transl Med. 2019 Dec 13;17(1):417. (PMID: 31836011) ; J Acquir Immune Defic Syndr. 2015 May 1;69(1):11-7. (PMID: 25647525) ; AIDS. 2019 Jun 1;33(7):1117-1129. (PMID: 30789356) ; Viral Immunol. 2012 Aug;25(4):333-7. (PMID: 22788418) ; PLoS One. 2014 Dec 29;9(12):e115226. (PMID: 25544986) ; J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):e47-9. (PMID: 22327247) ; Enferm Infecc Microbiol Clin. 2011 Nov;29(9):645-53. (PMID: 21820763) ; Infect Genet Evol. 2018 Jan;57:51-58. (PMID: 29122683) ; HIV Med. 2015 Oct;16(9):553-62. (PMID: 25944318) ; J Leukoc Biol. 2002 Apr;71(4):669-76. (PMID: 11927654) ; PLoS Pathog. 2016 Aug 10;12(8):e1005774. (PMID: 27509048) ; Sci Rep. 2017 Aug 14;7(1):8104. (PMID: 28808319) ; Lancet. 2014 Jun 28;383(9936):2222-31. (PMID: 24698485) ; Cytokine. 2019 Mar;115:97-103. (PMID: 30472104) ; Viruses. 2023 Jan 04;15(1):. (PMID: 36680195) ; Front Immunol. 2018 Jan 05;8:1925. (PMID: 29354131) ; J Acquir Immune Defic Syndr. 2020 Apr 15;83(5):475-478. (PMID: 31917753) ; AIDS. 2011 Sep 24;25(15):1823-32. (PMID: 21572306) ; J Immunol. 2005 Apr 15;174(8):4892-900. (PMID: 15814716) ; Front Immunol. 2021 Aug 10;12:656663. (PMID: 34447368) ; N Engl J Med. 2013 Nov 7;369(19):1807-18. (PMID: 24195548) ; AIDS. 2013 Oct 23;27(16):2505-17. (PMID: 24096630) ; BMC Infect Dis. 2014 Mar 04;14:122. (PMID: 24589015) ; HIV Med. 2019 Oct;20(9):571-580. (PMID: 31148335) Contributed Indexing: Keywords: HIV-1 viral decay; IP-10; MIG; antiretroviral treatment; biomarkers Substance Nomenclature: 82115-62-6 (Interferon-gamma) ; 0 (Chemokine CXCL10) ; 0 (HIV Integrase Inhibitors) Entry Date(s): Date Created: 20231103 Date Completed: 20231106 Latest Revision: 20231106 Update Code: 20231215 PubMed Central ID: PMC10619723

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors.